trending Market Intelligence /marketintelligence/en/news-insights/trending/xa5xjknhp6bjlpjs2hl6dq2 content esgSubNav
In This List

Kitov Pharma acquires additional stake in TyrNovo

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Kitov Pharma acquires additional stake in TyrNovo

Kitov Pharma Ltd. acquired an additional 3.1% stake in its majority owned unit TyrNovo Ltd.

The Israel-based biopharmaceutical company acquired the stake from Taoz – Company for Management and Holdings of Cos. Ltd., in exchange for 0.9% of Kitov stock, comprising 2,816,900 newly issued ordinary shares or 140,845 American depositary shares.

Kitov Pharma now owns about 97.1% of TyrNovo, with the remaining 2.9% owned by TyrNovo founder and Chief Technology Officer Hadas Reuveni.